LakeShore Biopharma Co Ltd
LSB0.720USD
-0.010-1.37%
交易中 （美東）報價延遲15分鐘
13.74M總市值
--本益比TTM
關於 LakeShore Biopharma Co Ltd 公司
LakeShore Biopharma Co Ltd（原名 YS Biopharma Co Ltd）是一家生物製藥公司，致力於發現、開發、生產和商業化新一代傳染病和癌症疫苗和治療性生物製劑。公司的疫苗產品 YSJATM 狂犬病疫苗已實現商業化。公司還有四種處於不同臨牀開發階段的候選產品，包括 PIKA 狂犬病疫苗、PIKA 重組 COVID-19 疫苗、PIKA YS-ON-001 和 PIKA YS-HBV-001，以及四種臨牀前階段的候選產品，針對具有巨大醫療需求的 HBV、流感和癌症。此外，公司正在研究一系列處於發現階段的治療靶點、狂犬病和產品。
公司簡介
公司代碼LSB
公司名稱LakeShore Biopharma Co Ltd
上市日期Jul 30, 2021
CEOMr. Dave Chenn
員工數量758
證券類型Ordinary Share
年結日Jul 30
公司地址- -
城市- -
上市交易所NASDAQ Capital Market Consolidated
國家- -
郵編- -
電話- -
網址- -
公司代碼LSB
上市日期Jul 30, 2021
CEOMr. Dave Chenn
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Crystal Peak Investment Inc
41.22%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
TD Securities, Inc.
2.54%
Shao (Hui)
0.76%
Other
19.70%
持股股東
持股股東
佔比
Crystal Peak Investment Inc
41.22%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
TD Securities, Inc.
2.54%
Shao (Hui)
0.76%
Other
19.70%
股東類型
持股股東
佔比
Corporation
65.09%
Individual Investor
13.80%
Research Firm
2.54%
Investment Advisor
0.35%
Private Equity
0.34%
Investment Advisor/Hedge Fund
0.26%
Hedge Fund
0.03%
Other
17.60%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
28
16.97M
69.54%
+11.17M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
2023Q2
76
6.62M
71.12%
+3.57M
2023Q1
71
6.78M
73.08%
+4.90M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Apex Prospect Ltd
9.84M
51.55%
+9.84M
--
Feb 08, 2024
Zhang (Yi)
4.91M
25.73%
--
--
Feb 16, 2024
TD Securities, Inc.
1.05M
5.49%
+1.05M
--
Mar 31, 2025
Shao (Hui)
313.64K
1.64%
+108.76K
+53.09%
Jun 30, 2024
OrbiMed Advisors, LLC
140.43K
0.74%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
116.51K
0.61%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
75.18K
0.39%
--
--
Mar 31, 2025
Superstring Capital Management LP
30.79K
0.16%
--
--
Mar 31, 2025
Barclays Bank PLC
24.76K
0.13%
--
--
Mar 31, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
公告日期
類型
比率
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
